Global Veterinary PCD Pharma Franchise Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Veterinary PCD Pharma Franchise Market Research Report 2024
According to Mr Accuracy reports new survey, global Veterinary PCD Pharma Franchise market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Veterinary PCD Pharma Franchise market research.
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from £2.6bn in 2015 to £4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China's Pet Healthy Consumption of JD shows that in 2024, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China's pet medical market is about ¥67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 117%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Veterinary PCD Pharma Franchise market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Vee Remedies
Cure Up Pharma
Zenley
Biochemix
Ani Healthcare
Abiba Pharmacia
Sonika Lifesciences
Revital Cryogenic
Vetraise
Iskon Remedies
Reticine Pharmaids
Refit Animal Care
Uniray Lifesciences
Avibo
Altar Life
Kerwin Formulations
Trumac Healthcar
Mediganza Healthcare
Ayusun pharma
Petvet Healthcare
Nicosia International
Benkind Lifesciences
Yester Pharma
Elkos Healthcare
Vibcare Pharma
Segment by Type
Antibiotic
Feed Supplement
Spray
Others
Personal
Enterprise
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Veterinary PCD Pharma Franchise report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from £2.6bn in 2015 to £4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China's Pet Healthy Consumption of JD shows that in 2024, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China's pet medical market is about ¥67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 117%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Veterinary PCD Pharma Franchise market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Vee Remedies
Cure Up Pharma
Zenley
Biochemix
Ani Healthcare
Abiba Pharmacia
Sonika Lifesciences
Revital Cryogenic
Vetraise
Iskon Remedies
Reticine Pharmaids
Refit Animal Care
Uniray Lifesciences
Avibo
Altar Life
Kerwin Formulations
Trumac Healthcar
Mediganza Healthcare
Ayusun pharma
Petvet Healthcare
Nicosia International
Benkind Lifesciences
Yester Pharma
Elkos Healthcare
Vibcare Pharma
Segment by Type
Antibiotic
Feed Supplement
Spray
Others
Segment by Application
Personal
Enterprise
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Veterinary PCD Pharma Franchise report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source